Viratek
Executive Summary
Parent ICN to purchase up to 500,000 additional shares, or approximately 5%, of the ribavirin developer over the next 12 months. As of Aug. 31, ICN said it had 170,050 shares of Viratek stock remaining to be purchased under a 1 mil. share purchase program announced Aug. 4, 1987, ICN, which currently owns over 70% of Viratek, has also authorized the purchase of up to 3 mil. shares of its 17 mil. outstanding common shares over the next two years.
You may also be interested in...
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.
Turning That Frown Upside Down: Treating Depression With Facial Botox Injections
In this episode of the In Vivo podcast, Eric Finzi, CEO of Healis Therapeutics, discusses how his company is targeting major depression, post-traumatic stress disorder and other mental illnesses using facial botox injections.
California Bill To Age-Restrict Sales Of Diet Pills Further Along Than Other States’ Legislation
CA, MA and NJ legislatures remain in session with bills active proposing regulations similar to NY law effective 22 April requiring retailers, including online, to ask for proof of age when customers buying consumer health products containing ingredients labeled or promoted for weight loss and bodybuilding benefits appear younger than 18.